CJC-1295 on its own record
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone based on the GRF(1-29) fragment, modified at several positions to resist enzymatic degradation. Two distinct versions circulate under the same name — one with a drug affinity complex (DAC) and one without — and they are not equivalent materials. VaultLabs supplies CJC-1295 as a reference material for in vitro laboratory research only.
Chemical name: CJC-1295 (GRF(1-29) analogue).
Common synonyms: Modified GRF 1-29 (no-DAC form), CJC-1295 DAC.
Parent sequence: Growth hormone-releasing hormone fragment 1-29.
Receptor target: GHRH receptor.
CJC-1295 (no DAC) 5mg + Ipamorelin 5mg is the 5 mg + 5 mg lyophilized unit, listed at AED 399 before VAT. The product record stores that sealed unit at 2–8 °C.
How CJC-1295 differs from the linked records
CJC-1295 versus Ipamorelin. Ipamorelin is a GHRP-class selective secretagogue — frequently co-referenced with CJC-1295 in literature but distinct sequence and receptor profile. No CAS for Ipamorelin is copied onto this page. A certificate for Ipamorelin does not qualify a CJC-1295 vial, and the reverse is also true. Read Ipamorelin on its own monograph rather than inferring it from this page.
CJC-1295 versus Retatrutide. CJC-1295 is catalogued as a GHRH analog peptide. Retatrutide is catalogued as a Multi-receptor agonist peptide (research literature) (Metabolic pathway research). They are separate records. Retatrutide is listed with CAS 2381089-83-2. A certificate for Retatrutide does not qualify a CJC-1295 vial, and the reverse is also true. Read Retatrutide on its own monograph rather than inferring it from this page.
Certificates do not cross over
Lot 238930 for CJC-1295 (no DAC) 5mg + Ipamorelin 5mg is a Janoshik Analytical report. The published record states Content reported. Figures printed on the report: Ipamorelin 4.83 mg; CJC-1295 (mod GRF 1-29) 4.68 mg. Method line on that report: CJC No DAC - MOD GRF (1-29)/Ipamorelin blend analysis. The laboratory file is linked from the certificate page. Open CJC-1295 (no DAC) 5mg + Ipamorelin 5mg certificate or match lot 238930 in batch verification. That report qualifies this lot only.
Lot VL-CJCIPA-20260321 is the catalogue certificate for CJC-1295 (no DAC) 5mg + Ipamorelin 5mg. Read it on CJC-1295 (no DAC) 5mg + Ipamorelin 5mg certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
CJC-1295 has both a laboratory report and catalogue certificates. Janoshik Analytical lot 238930 is the third-party file. The other lot numbers are catalogue certificates for their own fills. Match the printed lot. Do not treat one purity line as the result for every vial.
If a purchase order says CJC-1295, a vial of a related compound does not satisfy it. If the order names a strength, a different strength of CJC-1295 does not satisfy it either.
What this comparison refuses to do
It does not rank CJC-1295 against another material, recommend a combination, or translate a paper into a dose. VaultLabs does not provide dosage, administration, study-design, or medical guidance.
Prices and the literature notes are on the CJC-1295 research summary. Sealed-unit handling is the CJC-1295 storage guide. The CJC-1295 compound monograph remains the long record.
VaultLabs dispatches CJC-1295 from Dubai. Orders leave fulfillment within 24 hours, 7 days a week. Standard delivery is AED 35 to every emirate, and delivery is free when the post-discount merchandise subtotal is AED 500 or more. Checkout shows the fee for the address entered. All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use. VaultLabs does not provide dosage, administration, study-design, or medical guidance.